Gene expression profiling has revealed that diffuse large<unk> -cell lymphoma (DLBCL) is composed of at least 3 different sub-groups, each having distinct oncogenic mechanisms that respond to therapies in different ways.<unk><unk> <unk> -Cell<unk>  (GCB) DLBCLs appear to arise from normal<unk><unk> <unk>  cells, while Activated<unk> -cell<unk>  (ABC) DLBCLs are thought to arise from postgerminal<unk> <unk>  cells that are arrested during plasmacytic differentiation. The differences in gene expression<unk> etween GCB DLBCL and ABC DLBCL are as vast as the differences<unk> etween distinct types of leukemia,<unk> ut these conditions have historically<unk> een grouped together and treated as the same disease.
Germinal center B-cell like diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma associated with chronic inflammation
Epstein–Barr virus positive diffuse large B-cell lymphoma, not otherwise specified
T cell/histiocyte-rich large B-cell lymphoma
Nodular lymphocyte predominant Hodgkin lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman's disease
Pediatric-type follicular lymphoma